{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:08:55Z","timestamp":1784581735233,"version":"3.55.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background and Aims:<\/jats:bold> Granulocyte colony-stimulating factor (G-CSF) has been proposed as a therapeutic option for patients with acute-on-chronic liver failure (ACLF). However, its clinical efficacy remains debatable. This study aimed to synthesize available evidence on the efficacy of G-CSF in ALCF.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The Cochrane Library, CNKI, MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched from inception until September 2021. After qualitative evaluation of the included literature, the included studies were analyzed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Seven studies were included in this meta-analysis. Overall, G-CSF therapy was not associated with a reduced risk of death (30-day survival, OR = 1.55, 95% CI: 1.00, 2.38, <jats:italic>P<\/jats:italic> = 0.05; 60-day survival, OR = 1.50, 95% CI: 0.95, 2.36, <jats:italic>P<\/jats:italic> = 0.08; 90-day survival, OR = 1.61, 95% CI: 0.99, 2.62, <jats:italic>P<\/jats:italic> = 0.05) or complication including occurrence of infections infection (OR = 0.66, 95% CI: 0.41, 1.05, <jats:italic>P<\/jats:italic> = 0.08), bleeding (OR = 1.50, 95% CI: 0.58, 3.89, <jats:italic>P<\/jats:italic> = 0.41), and hepatorenal syndrome (OR = 0.56, 95% CI: 0.25, 1.24, <jats:italic>P<\/jats:italic> = 0.15). Moreover, it had no obvious beneficial effects on the model of end-stage liver disease score (30-day SMD = \u22123.31, 95%CI: \u22127.42, 0.81, <jats:italic>P<\/jats:italic> = 0.12; 60-day SMD = \u22121.23, 95% CI: \u22125.21, 2.75, <jats:italic>P<\/jats:italic> = 0.54; 90-day SMD = \u22122.29, 95%CI: \u22124.94, 0.37, <jats:italic>P<\/jats:italic> = 0.09). Sensitivity analyses showed that patients in Asia had improved survival (30-day OR = 2.76, 95%CI: 1.43, 5.35, <jats:italic>P<\/jats:italic> = 0.003; 60-day OR = 2.83, 95% CI: 1.39, 5.73, <jats:italic>P<\/jats:italic> = 0.004; 90-day OR = 2.92, 95% CI: 1.34, 6.36, <jats:italic>P<\/jats:italic> = 0.007).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Our findings suggest that, currently, G-CSF cannot be recommended for the treatment of ACLF.<\/jats:p>","DOI":"10.3389\/fmed.2021.784240","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:17:27Z","timestamp":1637043447000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic Effect and Safety of Granulocyte Colony-Stimulating Factor Therapy for Acute-On-Chronic Liver Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"8","author":[{"given":"Xiaoxue","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanlong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1002\/hep.28812","article-title":"Time trends in the health care burden and mortality of acute on chronic liver failure in the United States","volume":"64","author":"Allen","year":"2016","journal-title":"Hepatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/lt.25332","article-title":"Current status and future challenges of liver transplantation programs in Chile","volume":"24","author":"Ben\u00edtez","year":"2018","journal-title":"Liver Transpl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jhep.2021.03.030","article-title":"Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA\/EF-CLIF collaborative study (ECLIS)","volume":"75","author":"Belli","year":"2021","journal-title":"J Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1055\/s-0041-1723034","article-title":"The current status of granulocyte-colony stimulating factor to treat acute-on-chronic liver failure","volume":"41","author":"Engelmann","year":"2021","journal-title":"Semin Liver Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1053\/j.gastro.2011.11.027","article-title":"Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure","volume":"142","author":"Garg","year":"2012","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3748\/wjg.v19.i7.1104","article-title":"Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure","volume":"19","author":"Duan","year":"2013","journal-title":"World J Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/hep.29763","article-title":"Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: a randomized trial","volume":"68","author":"Verma","year":"2018","journal-title":"Hepatology."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.07.033","article-title":"Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study)","author":"Engelmann","year":"2021","journal-title":"J Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s12072-017-9814-1","article-title":"Therapeutic implications of granulocyte colony stimulating factor in patients with acute-on-chronic liver failure: increased survival and containment of liver damage","volume":"11","author":"Saha","year":"2017","journal-title":"Hepatol Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jceh.2019.10.001","article-title":"Role of granulocyte colony stimulating factor on the short-term outcome of children with acute on chronic liver failure","volume":"10","author":"Sharma","year":"2020","journal-title":"J Clin Exp Hepatol."},{"key":"B11","first-page":"279","article-title":"Randomized controlled clinical study of granulocyte colony stimulating factor in the treatment of chronic hepatitis B-related acute liver failure","volume":"29","author":"Xu","year":"2016","journal-title":"Infect Dis Inf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5005\/jp-journals-10018-1330","article-title":"Effect of granulocyte colony-stimulating factor and erythropoietin on patients with acute-on-chronic liver failure","volume":"10","author":"Haque","year":"2020","journal-title":"Euroasian J Hepatogastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12072-017-9834-x","article-title":"Improving survival in ACLF: growing evidence for use of G-CSF","volume":"11","author":"Simonetto","year":"2017","journal-title":"Hepatol Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1665-2681(19)30757-4","article-title":"Granulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysis","volume":"14","author":"Chavez-Tapia","year":"2015","journal-title":"Ann Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"100211","DOI":"10.1016\/j.aohep.2020.04.011","article-title":"Granulocyte colony stimulating factor: a potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis","volume":"20","author":"Rathi","year":"2021","journal-title":"Ann Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/liv.12356","article-title":"Beneficial role of G-CSF in acute-on-chronic liver failure: effects on liver regeneration, inflammation\/immunoparalysis or both?","volume":"34","author":"Gustot","year":"2014","journal-title":"Liver Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.hbpd.2019.07.003","article-title":"The immunological roles in acute-on-chronic liver failure: an update","volume":"18","author":"Chen","year":"2019","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0140-6736(15)00309-8","article-title":"Acute-on-chronic liver failure","volume":"386","author":"Bernal","year":"2015","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122158","article-title":"Comparison of current diagnostic criteria for acute-on-chronic liver failure","volume":"10","author":"Zhang","year":"","journal-title":"PLoS ONE"},{"key":"B20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.14218\/JCTH.2016.00012","article-title":"Effects of granulocyte colony-stimulating factor on patients with liver failure: a meta-analysis","volume":"4","author":"Yang","year":"2016","journal-title":"J Clin Transl Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.784240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:17:30Z","timestamp":1637043450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.784240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":20,"alternative-id":["10.3389\/fmed.2021.784240"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.784240","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"article-number":"784240"}}